LNCD(SH:600739)2021-04-29 16:00Financial Performance - Net profit attributable to shareholders surged by 314.05% to CNY 534.14 million year-on-year[4] - Operating revenue rose by 20.06% to CNY 3.97 billion compared to the same period last year[4] - Basic earnings per share increased by 314.23% to CNY 0.3492[4] - The weighted average return on equity improved by 1.60 percentage points to 2.20%[4] - Total operating revenue for Q1 2021 reached ¥3,971,413,484.63, an increase of 20.05% compared to ¥3,307,823,985.10 in Q1 2020[15] - Net profit for Q1 2021 was ¥682,470,622.67, a significant increase from ¥97,635,131.34 in Q1 2020, representing a growth of 698.67%[15] - Earnings per share for Q1 2021 was ¥0.3492, compared to ¥0.0843 in Q1 2020, reflecting a substantial increase[16] Assets and Liabilities - Total assets increased by 4.27% to CNY 40.83 billion compared to the end of the previous year[4] - Total current assets amounted to 8,058,119,115.94, up from 6,764,492,410.44 in the previous year[9] - Current liabilities rose to ¥11,183,081,157.09, compared to ¥9,596,786,086.22, marking an increase of about 16.54%[10] - Total liabilities increased to ¥15,212,831,169.68 from ¥14,151,380,251.83, representing a growth of approximately 7.49%[11] - The total equity increased to ¥25,618,463,589.15 from ¥25,006,236,024.15, showing a growth of approximately 2.44%[11] - The company’s long-term investments increased to ¥29,431,712,948.54 from ¥29,080,690,470.84, reflecting a growth of about 1.21%[12] - The total assets of the company increased to ¥38,061,241,506.22 in Q1 2021 from ¥36,622,426,910.71 in Q1 2020, representing a growth of 3.94%[13] Cash Flow - Net cash flow from operating activities decreased by 74.54% to -CNY 177.70 million compared to the previous year[4] - Cash flow from operating activities showed a net outflow of CNY -177,695,149.52 in Q1 2021, worsening from CNY -101,806,909.27 in Q1 2020[19] - Cash flow from investing activities resulted in a net outflow of CNY -629,860,478.46 in Q1 2021, compared to a net inflow of CNY 7,317,247.15 in Q1 2020[20] - Cash flow from financing activities generated a net inflow of CNY 1,142,241,596.69 in Q1 2021, a significant increase from CNY -24,105,355.66 in Q1 2020[20] - The cash and cash equivalents at the end of Q1 2021 amounted to CNY 2,447,263,322.35, up from CNY 1,797,725,259.23 at the end of Q1 2020[20] Investments and Subsidiaries - Investment income rose by 39.43% to 401,782,219.58, primarily due to increased returns from joint ventures[7] - The company plans to spin off its subsidiary, Liaoning Chengda Biological Co., Ltd., for a listing on the Sci-Tech Innovation Board, pending regulatory approval[8] - The company reported a loss of CNY 18.92 million from fair value changes of financial assets[5] - The company achieved a net profit of CNY 7.01 million from the reversal of impairment provisions on receivables[5] Shareholder Information - The number of shareholders at the end of the reporting period was 70,264, with the top ten shareholders holding a combined 38.20% of the shares[6] - Minority interests after tax amounted to CNY 1.44 million[5] Expenses - The company reported a decrease in sales expenses by 56.61% to 115,825,504.41, attributed to the disposal of a subsidiary in the previous year[7] - Research and development expenses for Q1 2021 were ¥64,259,108.26, an increase from ¥57,803,155.69 in Q1 2020, reflecting a growth of 11.25%[15] - The company recorded a decrease in management expenses to CNY 31,212,523.60 in Q1 2021 from CNY 19,605,658.77 in Q1 2020, indicating a rise of 59.2%[17]